English
norskBlar i forfatter "Mauseth, Brynjar"
Viser treff 1-7 av 7
-
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
(Journal article; Tidsskriftartikkel; Peer reviewed, 2019-01-22)<i>Background</i> - Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death through the release of danger-associated molecular pattern molecules (DAMPs), LTX-315 is capable ... -
The cytolytic amphipathic β(2,2)-amino acid LTX-401 induces DAMP release in melanoma cells and causes complete regression of B16 melanoma
(Journal article; Tidsskriftartikkel; Peer reviewed, 2016)In the present study we examined the ability of the amino acid derivative LTX-401 to induce cell death in cancer cell lines, as well as the capacity to induce regression in a murine melanoma model. Mode of action studies in vitro revealed lytic cell death and release of danger-associated molecular pattern molecules, preceded by massive cytoplasmic vacuolization and compromised lysosomes in treated ... -
The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma
(Journal article; Tidsskriftartikkel; Peer reviewed, 2019-05-21)LTX-401 is a novel oncolytic compound designed for the local treatment of solid tumors. In the present study, we have examined the applicability and efficacy of LTX-401 in a rat model JM1 hepatocellular carcinoma, with particular interest in its ability to induce antitumor immunity. LTX-401 induces necrotic cell death followed by the release of immunogenic cell death mediators such as high-mobility ... -
Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals
(Journal article; Tidsskriftartikkel; Peer reviewed, 2018-10-23)Abstract Oncolytic peptides and peptidomimetics are being optimized for the treatment of cancer by selecting agents with high cytotoxic potential to kill a maximum of tumor cells as well as the capacity to trigger anticancer immune responses and hence to achieve long-term effects beyond therapeutic discontinuation. Here, we report on the characterization of two novel oncolytic peptides, DTT-205 ... -
Oncolytic Activity and Mechanisms of Action by a small β2,2-amino acid derivative LTX-401
(Master thesis; Mastergradsoppgave, 2015-05-11)Antimicrobial peptides are part of the innate immune defence of many organisms and represent a novel class of therapeutics due to their broad-spectrum activities, including cytotoxic activity against cancer cells. It has recently been reported that small antimicrobial β2,2-amino acid derivatives (Mw<500), such as LTX-401, possess potent anticancer activity against Ramos human Burkitt’s lymphoma ... -
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
(Journal article; Tidsskriftartikkel; Peer reviewed, 2021-03-24)Oncolytic peptides represent a novel, promising cancer treatment strategy with activity in a broad spectrum of cancer entities, including colorectal cancer (CRC). Cancer cells are killed by immunogenic cell death, causing long-lasting anticancer immune responses, a feature of particular interest in non-immunogenic CRC. Oncolytic peptides DTT-205 and DTT-304 were administered by intratumoral injection ... -
Tumor lysis with LTX-401 creates anticancer immunity
(Journal article; Tidsskriftartikkel; Peer reviewed, 2019-04-13)Local immunotherapies such as the intratumoral injection of oncolytic compounds aim at reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, we show that LTX-401, yet another oncolytic compound designed for local immunotherapy, depicts a similar safety profile and ...
